TY - JOUR
T1 - Maintenance IV immunoglobulin treatment in chronic inflammatory demyelinating polyradiculoneuropathy
AU - Kuitwaard, Krista
AU - Fokkink, Willem-Jan R.
AU - Brusse, Esther
AU - Vrancken, Alexander F. J. E.
AU - Eftimov, Filip
AU - Notermans, Nicolette C.
AU - van der Kooi, Anneke J.
AU - Merkies, Ingemar S. J.
AU - Jacobs, Bart C.
AU - van Doorn, Pieter A.
PY - 2017
Y1 - 2017
N2 - Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) patients treated with intravenous immunoglobulin (IVIg) usually start with a standard dosage of 2g/kg bodyweight. Only a minority of patients has a sustained improvement, and most require ongoing maintenance treatment. Preferred IVIg regimens, however, vary considerably between doctors and at present it is unknown which is optimal. As there are also large differences in IVIg dosage and interval requirements between patients, optimal IVIg maintenance treatment of CIDP is even more complex. The lack of evidence-based guidelines on how IVIg maintenance treatment should be administered may potentially lead to under- or overtreatment of this expensive therapy. We provide an overview of published practical IVIg maintenance treatment regimens, IVIg maintenance schedules used in randomized controlled trials and one based upon our own long-term experience on how this treatment could be given in CIDP
AB - Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) patients treated with intravenous immunoglobulin (IVIg) usually start with a standard dosage of 2g/kg bodyweight. Only a minority of patients has a sustained improvement, and most require ongoing maintenance treatment. Preferred IVIg regimens, however, vary considerably between doctors and at present it is unknown which is optimal. As there are also large differences in IVIg dosage and interval requirements between patients, optimal IVIg maintenance treatment of CIDP is even more complex. The lack of evidence-based guidelines on how IVIg maintenance treatment should be administered may potentially lead to under- or overtreatment of this expensive therapy. We provide an overview of published practical IVIg maintenance treatment regimens, IVIg maintenance schedules used in randomized controlled trials and one based upon our own long-term experience on how this treatment could be given in CIDP
U2 - https://doi.org/10.1111/jns.12242
DO - https://doi.org/10.1111/jns.12242
M3 - Review article
C2 - 29092099
SN - 1085-9489
VL - 22
SP - 425
EP - 432
JO - Journal of the peripheral nervous system
JF - Journal of the peripheral nervous system
IS - 4
ER -